Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming that the drug infringed a US patent (No. 9,662,335) ...

NHS England has started a pilot trial of an iPhone app and device combination that could be used by nursing staff to speed up ...

Generic drugmaker Accord Healthcare has announced a £50 million ($65 million) investment in the UK that will include the ...

Lawyers for AstraZeneca, Bristol-Myers Squibb, and Johnson & Johnson argued at a panel hearing in Philadelphia late last week ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated ...

Between digital therapeutics, HCP portals, and patient support communications, pharma companies are investing a significant portion of their revenues on digital products. To justify spending ...

Telehealth company Talkiatry has partnered with Biogen to expand its support service for women who develop postpartum depression (PPD) in a move that could help drive uptake of the latter's new ...

Victor Ambros (l) and Gary Ruvkun (r) share the 2024 Nobel Prize in Physiology or Medicine Victor Ambros and Gary Ruvkun have shared this year's Nobel Prize in Physiology or Medicine for their ...

The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to be funded by the NHS, according to cost-effectiveness watchdog NICE.

Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy Leqembi, saying its efficacy does not outweigh its risks. Explaining its ...

UK actor and TV personality Nadia Sawalha is spearheading a fundraising effort to launch an appeal against the recent rejection of a breast cancer therapy by cost-effectiveness agency NICE.

A phase 3 trial of Johnson & Johnson's TAR-200 therapy in bladder cancer has failed to show efficacy, although the company is still confident in the potential of the programme. The SunRISe-2 study ...